(MedPage Today) — At the recent American Society of Clinical Oncology (ASCO) annual meeting, interim results from the DESTINY-Breast09 trial highlighted a potential shift in frontline treatment for metastatic HER2-positive breast cancer. The combination…
Source link : https://www.medpagetoday.com/meetingcoverage/ascovideopearlsbreastca/116216
Author :
Publish date : 2025-06-24 15:23:00
Copyright for syndicated content belongs to the linked Source.
